DDInter1513 DDInter1658
Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Prednisolone {u} (Compound) resembles {v} (Compound) Fluprednidene Acetate
Prednisolone {u} (Compound) resembles {v} (Compound) Hydrocortamate
Prednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Testosterone
Prednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluoxymesterone
Prednisolone {u} (Compound) treats {v} (Disease) chronic obstructive pulmonary disease
Prednisolone {u} (Compound) binds {v} (Gene) NR3C1
Prednisolone {u} (Compound) upregulates {v} (Gene) NFKBIA
Prednisolone {u} (Compound) palliates {v} (Disease) idiopathic pulmonary fibrosis
Prednisolone {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Prednisolone {u} (Compound) downregulates {v} (Gene) FHL2
Prednisolone (Compound) resembles Fluprednidene Acetate (Compound)
Prednisolone (Compound) resembles Hydrocortamate (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Testosterone
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Fluoxymesterone
Prednisolone (Compound) treats chronic obstructive pulmonary disease (Disease)
Prednisolone (Compound) binds NR3C1 (Gene)
Prednisolone (Compound) upregulates NFKBIA (Gene)
Prednisolone (Compound) palliates idiopathic pulmonary fibrosis (Disease)
Prednisolone (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Prednisolone (Compound) downregulates FHL2 (Gene)